The Real Cost of GLP-1 Medications in 2026 (With and Without Insurance)

GLP-1 medications are among the most clinically effective weight management and diabetes treatments ever developed — and among the most expensive medications in American pharmacies. A single month's supply of Wegovy or Zepbound lists at over $1,000. For many patients, the biggest barrier to treatment isn't side effects or injections — it's the monthly bill.

This guide breaks down the actual 2026 pricing landscape: list prices, what insurance typically pays, manufacturer savings programs, GoodRx, and alternatives including compounded versions. Numbers here are as current as possible, but drug pricing changes frequently — always verify at the pharmacy counter and use our cost estimator for real-time comparisons.

List Prices in 2026

"List price" is the sticker price before any insurance adjustment, discount card, or coupon is applied. Very few patients pay list price, but it establishes the ceiling.

Medication	Active Ingredient	Indication	Approx. List Price/Month
Ozempic 0.5 mg	Semaglutide	Type 2 diabetes	~$935
Ozempic 1 mg	Semaglutide	Type 2 diabetes	~$935
Ozempic 2 mg	Semaglutide	Type 2 diabetes	~$990
Wegovy 2.4 mg	Semaglutide	Obesity/CVD risk	~$1,349
Mounjaro 5–15 mg	Tirzepatide	Type 2 diabetes	~$1,069
Zepbound 5–15 mg	Tirzepatide	Obesity/CVD risk	~$1,059
Saxenda (3 mg daily)	Liraglutide	Obesity	~$1,349

Prices based on manufacturer list prices and GoodRx data as of May 2026. Prices vary by pharmacy and region.

The relative pricing parity between semaglutide and tirzepatide products is notable — tirzepatide (Mounjaro/Zepbound) is slightly less expensive by list price despite producing larger average weight loss, reflecting competitive market dynamics since Zepbound's 2023 launch.

What Insurance Actually Pays

Coverage varies enormously based on insurance type, plan design, diagnosis, and formulary tier.

Commercial Insurance (Employer-Sponsored or Individual Market)

For diabetes (Ozempic, Mounjaro): Most commercial plans cover Ozempic and Mounjaro for type 2 diabetes, typically on Tier 3 or Tier 4 (specialty tier). Patient cost-sharing ranges from $50–$200/month with a standard commercial plan, or up to $400+/month on high-deductible plans before meeting the deductible.

For obesity (Wegovy, Zepbound): Coverage is inconsistent. A 2023 survey by the Obesity Medicine Association found that fewer than 40% of commercially insured Americans have obesity medication coverage through their employer plan. Coverage has been expanding as employer cost-benefit analyses show ROI — particularly large self-insured employers — but exclusions remain common.

Key check: Call your insurance's member services and ask specifically: "Is Wegovy [or Zepbound] covered on my formulary for obesity with a BMI of [your BMI]? What is my cost-sharing?" Don't rely on general coverage lists.

Medicare

• Ozempic and Mounjaro: Covered under Medicare Part D for type 2 diabetes
• Wegovy and Zepbound: As of 2026, Medicare Part D covers Wegovy and Zepbound for patients who have established cardiovascular disease (following the 2024 FDA indication expansions based on the SELECT trial). Coverage for obesity alone, without CVD, remains limited under Medicare Part D as a result of the exclusion of obesity drugs in the Medicare Modernization Act of 2003. This legislative exclusion has been the target of the Treat and Reduce Obesity Act, which as of this publication has not been passed.

Medicaid

Coverage varies by state. Some state Medicaid programs cover GLP-1 medications for diabetes; coverage for obesity is more variable. Check your state's Medicaid formulary or contact your state's Medicaid office directly.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly operate savings programs that can dramatically reduce out-of-pocket costs for commercially insured patients.

Novo Nordisk (Ozempic, Wegovy)

Ozempic Savings Card: - Eligible commercially insured patients may pay as little as $25/month for up to 24 months - Not available to Medicare, Medicaid, or uninsured patients - Enrollment at ozempic.com/savings

Wegovy Savings Program: - Eligible commercially insured patients may pay as little as $0/month for the first month, then varying rates based on insurance - Program enrollment and eligibility at wegovy.com - Also not available to federal program beneficiaries (Medicare/Medicaid)

Eli Lilly (Mounjaro, Zepbound)

Mounjaro Savings Card: - Eligible commercially insured patients may pay as little as $25/month - Enrollment at mounjaro.com

Zepbound Savings Program: - Eligible commercially insured patients may pay as little as $25/month - Lilly also offers LillyDirect, a direct-to-patient self-pay program: - Doses 2.5 mg and 5 mg: approximately $349/month - Doses 7.5 mg, 10 mg, 12.5 mg: approximately $499/month - Dose 15 mg: approximately $549/month - LillyDirect self-pay applies regardless of insurance status — it's Lilly's response to access and affordability concerns

GoodRx and Discount Cards

GoodRx is a free service that negotiates discounted prescription prices with pharmacies. For GLP-1 medications, GoodRx discounts are typically modest compared to manufacturer savings programs — but they are available to uninsured patients and those on Medicare, who cannot use manufacturer savings cards.

Typical GoodRx prices (May 2026, varies by pharmacy): - Ozempic 1 mg: ~$850–$950/month at major chains - Wegovy 2.4 mg: ~$1,100–$1,300/month - Mounjaro 10 mg: ~$950–$1,050/month - Zepbound 10 mg: ~$900–$1,000/month

GoodRx is most useful for lower-dose tiers and for comparison shopping between pharmacies. Mark Cuban's Cost Plus Drugs (costplusdrugs.com) does not currently carry brand-name GLP-1 injectables but is worth monitoring as the market evolves.

Compounded Semaglutide and Tirzepatide

During shortage periods (2022–2024), the FDA permitted compounding pharmacies to produce copies of semaglutide and tirzepatide. Compounded versions are significantly cheaper:

• Compounded semaglutide: ~$150–$350/month (telehealth platforms including Hims & Hers, Ro, Mochi Health, Calibrate)
• Compounded tirzepatide: ~$200–$400/month

However, the regulatory situation is complex and evolving:

These medications are investigational or compounded and not FDA-approved for weight loss. Information here is educational only — not a recommendation. Do not source medications from unverified suppliers.

The FDA's shortage designation — which authorized compounding — was lifted for tirzepatide in early 2025 and has been contested for semaglutide. As of May 2026, the legality of commercially compounded GLP-1s is in legal flux, with multiple lawsuits between compounders and the FDA. Before pursuing a compounded option, verify current FDA status at fda.gov/drugs/drug-safety-and-availability/drug-shortages and confirm your compounding pharmacy holds proper accreditation (503A or 503B facility designation). See our dedicated article on compounded GLP-1 safety and options.

Prior Authorization: The Hidden Time Cost

Even when insurance covers GLP-1 medications, prior authorization (PA) is nearly universal. PA requires your prescriber to submit documentation demonstrating medical necessity before the insurer will pay.

For obesity medications, typical PA requirements include: - BMI ≥30 (or ≥27 with documented comorbidity) - Documentation of prior weight loss attempts (diet programs, other medications) - Absence of contraindications - Sometimes: specialist referral or letter of medical necessity

PA approvals typically take 3–14 business days. Denials are common — but appeals succeed at meaningful rates. If denied, ask your prescriber for a peer-to-peer review (where your doctor speaks directly with the insurance medical director) — this is one of the most effective appeals strategies.

What Patients Actually Pay: Real-World Cost Distribution

A 2024 analysis published in JAMA Health Forum examined actual out-of-pocket costs for patients prescribed GLP-1 medications for obesity:

• Commercially insured with coverage: median ~$70/month after savings programs
• Commercially insured without coverage: median ~$660/month
• Medicare beneficiaries: median ~$500/month (before 2024 CVD indication expansion)
• Uninsured: median ~$1,050/month (list price minus any discount card savings)

These numbers explain why medication discontinuation rates are high among uninsured and underinsured patients — adherence drops sharply when out-of-pocket costs exceed $200/month.

Strategies to Reduce Your Cost

1. Confirm insurance coverage before starting. Call your insurer with your specific diagnosis code (E11.x for T2D, E66.x for obesity, Z68.x for BMI documentation).
2. Enroll in manufacturer savings programs if you're commercially insured — these are legitimate, legal, and can reduce costs to $0–$25/month.
3. If on Medicare with CVD: Verify Wegovy/Zepbound coverage under your Part D plan — the cardiovascular indication may trigger coverage.
4. If uninsured: Consider the LillyDirect self-pay program for Zepbound (starting ~$349/month), which is manufacturer-direct and uses the authentic branded product.
5. Use GoodRx for comparison. Even if you have insurance, GoodRx is occasionally cheaper than your insurance copay for certain pharmacies.
6. If appealed and denied: Contact the Obesity Action Coalition or your state insurance commissioner for appeals assistance.
7. Ask about dose flexibility: Some patients do well on doses below the maximum. At lower doses, cost is the same (pens are fixed), but maintaining a lower effective dose may be acceptable long-term.

Use our cost estimator to model your specific insurance and income scenario.

Independent Analysis: How the GLP-1 Cost Landscape Actually Works in 2026

Three structural observations about GLP-1 pricing that make out-of-pocket cost difficult to predict from list price alone:

1. The list-price-to-patient-cost gap is unusually large for these medications

For most branded prescription medications, out-of-pocket cost tracks somewhat predictably from list price through tiered copay structures. GLP-1 anti-obesity medications are unusual because two simultaneous pricing systems operate: the standard insurance adjudication pathway (which may or may not cover anti-obesity indication), and the manufacturer savings card pathway (which creates a near-zero floor for eligible commercially insured patients). The KFF 2024 analysis of GLP-1 coverage found that less than half of large employer plans covered Wegovy or Zepbound for obesity indication, yet manufacturer savings programs are widely used even when insurance does not cover the drug. The result is a cost landscape where two patients at the same employer with the same insurance can have wildly different monthly costs — one using a savings card at $25/month, another without knowledge of the program paying list price or discontinuing. Information access, not insurance status alone, determines what patients pay.

2. Lilly's vial program changes the self-pay math structurally

When Eli Lilly launched Zepbound single-dose vials through LillyDirect in late 2023 at $399–$549/month (depending on dose), it created a self-pay price point that bypasses the pharmacy benefit manager entirely. This is categorically different from a coupon or savings card — it is a direct-to-patient channel at a price the company sets, similar to insulin pricing reforms. The practical implication for self-pay patients is significant: at $399/month for tirzepatide 2.5 mg or 5 mg, the branded drug is now cost-competitive with many legitimate compounded tirzepatide offerings, eliminating the main financial argument for compounding at lower doses. At higher maintenance doses (10 mg, 15 mg), the vial program costs $499/month, still below the list price of Zepbound auto-injector pens. Novo Nordisk has not launched an equivalent program for Wegovy as of mid-2026, maintaining a larger branded-vs.-compounded price gap for semaglutide.

3. Medicare coverage is real but contingent on cardiovascular risk documentation

The FDA's 2024 approval of semaglutide (Wegovy) for cardiovascular risk reduction in patients with established cardiovascular disease — based on the SELECT trial — created a separate coverage pathway under Medicare Part D. Medicare is prohibited from covering weight loss drugs, but it can cover cardiovascular risk reduction drugs. Plans that have added Wegovy under this pathway cover it for patients who have documented atherosclerotic cardiovascular disease and BMI over 27 — not for weight loss alone. In practice, this means Medicare beneficiaries who qualify for Wegovy on cardiovascular grounds face very different cost structures than those who do not. Whether a given Part D plan has added Wegovy to its formulary varies. Patients should check their specific plan's formulary, not assume coverage from the FDA label.

What this means for planning medication costs

Before accepting a quoted price, most patients benefit from checking three things: whether their insurance covers the drug under anti-obesity or cardiovascular indication; whether the manufacturer savings card applies to their insurance type; and whether the LillyDirect vial program (for tirzepatide) represents a better self-pay price than their insurer's cost-sharing. These are not complicated steps, but they are not automated — the system does not route patients to the lowest available price. See our compounded GLP-1 guide for context on the cost-versus-risk tradeoff of compounded versions.

Frequently Asked Questions

How much does Wegovy cost per month in 2026?

Wegovy's list price is approximately $1,349/month as of 2026. With Novo Nordisk's NovoCare savings card, commercially insured patients may pay as little as $0–$25/month. Without insurance and without a savings card, self-pay patients pay near list price — though some specialty pharmacies negotiate modest discounts. Medicare and Medicaid enrollees cannot use manufacturer savings cards.

How much does Zepbound cost per month in 2026?

Zepbound auto-injector pens list at approximately $1,059/month. Through Eli Lilly's LillyDirect self-pay vial program, tirzepatide costs $349–$499/month depending on dose (2.5–5 mg at the lower price, 10–15 mg at the higher). Commercially insured patients using Lilly's savings card may pay $25/month or less. The vial program is the lowest-cost legal pathway for self-pay patients without insurance coverage.

Does insurance cover GLP-1 medications for weight loss?

Coverage is inconsistent and indication-dependent. A 2024 KFF analysis found that under half of large employer plans covered GLP-1 drugs for obesity specifically. Coverage for diabetes indication (Ozempic, Mounjaro) is more common. Medicare Part D covers Wegovy only for documented cardiovascular risk reduction, not for weight loss alone. Medicaid coverage varies by state. Always request a prior authorization if your first claim is denied — many plans cover GLP-1s under appeal.

Can I use GoodRx to reduce the cost of Wegovy or Zepbound?

GoodRx coupons typically produce minimal savings on high-list-price branded biologics like Wegovy and Zepbound compared to manufacturer programs. For most commercially insured patients, manufacturer savings cards (NovoCare for Wegovy, Lilly Savings Card for Zepbound) offer lower out-of-pocket cost than GoodRx. For truly uninsured patients, GoodRx may offer modest savings from list price, but the LillyDirect vial program is a better self-pay option for tirzepatide.

Will GLP-1 prices come down as patents expire?

Generic semaglutide is not expected until the early 2030s at the earliest, when Novo Nordisk's composition-of-matter patents expire. Biosimilar and generic competition typically reduces prices by 30–85% over several years post-expiry. Tirzepatide patents extend through approximately 2036. In the near term, price reduction for patients is more likely to come from expanded insurance coverage mandates and direct manufacturer pricing programs than from generic competition.

What is the NovoCare Patient Assistance Program?

NovoCare is Novo Nordisk's patient assistance program offering Wegovy at no cost to qualifying uninsured or underinsured patients with household income below certain thresholds (typically 400% of the federal poverty level). Eligibility and program terms can change; the current application process and income cutoffs are on the Novo Nordisk NovoCare website. This is different from the commercial savings card — it is for patients who do not have commercial insurance covering the drug.

Is compounded tirzepatide still legally available in 2026?

It depends on FDA shortage list status. The FDA placed tirzepatide on the shortage list in 2023, enabling 503A and 503B compounding pharmacies to produce it legally. Shortage designation can be removed or reinstated — check the current FDA Drug Shortage Database for tirzepatide's status before purchasing. If tirzepatide is no longer on the shortage list, compounding pharmacies are not permitted to produce bulk copies, and purchasing compounded tirzepatide would represent a regulatory violation.

Sources

1. Novo Nordisk. "Wegovy Savings Program." https://www.wegovy.com/coverage-and-cost/savings-program.html
2. Eli Lilly. "LillyDirect Zepbound Self-Pay Program." https://www.zepbound.lilly.com/savings
3. GoodRx. "GLP-1 Medication Price Comparison." https://www.goodrx.com/conditions/type-2-diabetes/glp-1-agonists
4. JAMA Health Forum. "Out-of-Pocket Costs for GLP-1 Medications for Obesity." 2024. https://jamanetwork.com/journals/jama-health-forum/fullarticle/2818033
5. KFF. "Claims Denials and Appeals in ACA Marketplace Plans." https://www.kff.org/private-insurance/issue-brief/claims-denials-and-appeals-in-aca-marketplace-plans/
6. FDA Drug Shortages. https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
7. Obesity Medicine Association. "Coverage for Anti-Obesity Medications." https://obesitymedicine.org/weight-loss-medications/